Related Experiment Video
Updated: Apr 15, 2026
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
Immunotherapeutic approaches to ovarian cancer treatment
Cariad Chester1, Oliver Dorigo2, Jonathan S Berek2
1Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA USA.
Abstract:
Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for ovarian cancer patients are inadequate. Immunotherapy offers a novel and promising therapeutic strategy for treating ovarian tumors. Following the demonstration of the immunogenicity of ovarian tumors, multiple immunotherapeutic modalities have been developed. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor-modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery.
Insights
Ovarian cancer immunotherapy shows promise despite current treatment limitations. Novel strategies like antibody therapy and vaccines are advancing, highlighting the need for combination treatments and biomarkers.
Area of Science:
- Oncology
- Immunology
- Cancer Therapy
Background:
- Current ovarian cancer treatments, including chemotherapy, remain inadequate for many patients.
- Ovarian tumors have demonstrated immunogenicity, paving the way for immunotherapy.
- Advances in immunotherapy offer a promising new avenue for ovarian cancer treatment.
Purpose of the Study:
- To review emerging immunotherapeutic approaches for ovarian cancer.
- To highlight the potential of novel strategies in overcoming treatment resistance.
- To emphasize the importance of combination therapies and biomarker discovery in ovarian cancer immunotherapy.
Main Methods:
- Review of preclinical and clinical data on ovarian cancer immunotherapy modalities.
- Discussion of antibody-based therapies.
- Exploration of immune checkpoint blockade, cancer vaccines, and CAR T-cell therapy.
Main Results:
- Multiple immunotherapeutic strategies have shown preclinical success.
- Approaches including antibody therapy, immune checkpoint blockade, vaccines, and CAR T-cells are entering clinical trials.
- The immunogenicity of ovarian tumors supports the development of these therapies.
Conclusions:
- Immunotherapy represents a novel and promising strategy for ovarian cancer.
- Combinatorial treatment approaches are crucial for maximizing therapeutic efficacy.
- Biomarker discovery is essential for personalizing ovarian cancer immunotherapy.
More Related Videos
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...